Athersys, Inc (ATHX)

Athersys Inc., the Cleveland-based regenerative medicine company, could raise up to $12 million by selling its shares and warrants to "a single healthcare-focused U.S. institutional investor." The unnamed institutional investor has agreed to acquire up to 48 million shares of Athersys stock, stock equivalents and warrants for 25 cents apiece in a deal expected to close by Aug. 17, the Cleveland company said in a Monday statement. Athersys, which is in the midst of a financial and operational restructuring, said it would use net proceeds from the sales "for general corporate purposes."

Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor for the purchase and sale of 48,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 48,000,000 shares of common stock at a purchase price per share (and accompanying warrant) of $0.25 in a registered direct offering. The warrants will have an exercise price of $0.2554 per share, will be initially exercisable beginning six months following the date of issuance and will expire five years from the initial exercise date.

Shareholders in Athersys, Inc. ( NASDAQ:ATHX ) may be thrilled to learn that the covering analyst has just delivered a...

ATHX earnings call for the period ending June 30, 2022.

In June, Athersys embarked on a financial and operational restructuring to lower its cost and conserve cash while commercialization its adult stem-cell therapy.

Athersys (NASDAQ:ATHX) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors ...

Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update.

Gainers ObsEva SA (NASDAQ: OBSV) shares rose 33.8% to $0.4080 in pre-market trading. ObsEva recently announced a $31 million debt ...

Athersys Inc(NASDAQ: ATHX) hasannounced the resultsof a radiation countermeasure study that showed intravenous ...

Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services University of the Health Sciences, that showed intravenous MultiStem® (invimestrocel) administration provided benefit in an animal model of acute radiation syndrome (ARS). The results demonstrate that the administration of MultiStem cells increased survival in treated animals compared to vehicle treatment (p=0.03), resulted in higher body weights in surviving animals and positive trends in recovery of the hematopoietic system.

CLEVELAND, August 08, 2022--Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services University of the Health Sciences, that showed intravenous MultiStem® (invimestrocel) administration provided benefit in an animal model of acute radiation syndrome (ARS). The results demonstrate that the administration

Athersys Inc., the Cleveland-based regenerative medicine company, has hired turnaround specialist Ankura Consulting Group LLC and appointed the firm's senior managing director, Kasey Rosado, as its interim chief financial officer. Athersys lost its previous CFO, Ivor Macleod, in June through a restructuring — which included cutting its workforce by as much as 70% — aimed at reducing costs and making it an attractive investment for potential financial or strategic partners. New York-based Ankura offers management consulting and expert services "at critical inflection points," including corporate restructuring, bankruptcy, dispute and litigation, according to its LinkedIn page.

Athersys Appoints Kasey Rosado as Interim Chief Financial Officer - Brings Operational Excellence and Financial Experience to Leadership Team

Athersys leaders want to consolidate the company's shares to raise their trading price and increase the number of shares that could be issued in the future.

Gainers MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company ...

Gainers Getty Images Holdings, Inc. (NYSE: GETY) shares climbed 149.1% to close at $26.15 on Friday following its merger with ...

Gainers NRX Pharmaceuticals (NASDAQ:NRXP) stock increased by 72.0% to $0.9 during Friday's regular session. As of ...

Gainers Getty Images Holdings, Inc. (NYSE: GETY) shares jumped 106.7% to $21.69 after nearly 99.4% of shares were redeemed by ...

Gainers Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is ...

Gainers Athersys (NASDAQ:ATHX) stock rose 73.2% to $0.33 during Thursday's regular session. The current volume of ...

Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) gained 231% to $2.63 on news that the company will be acquired By Henry Crown ...

Gainers Better Therapeutics (NASDAQ:BTTX) shares moved upwards by 67.3% to $2.56 during Thursday's pre-market ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! It's time for another dive into the biggest pre-market stock movers as we check out what's happening Thursday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” Cash Holders Could Get Hit Hard THIS FRIDAY

Gainers JAKKS Pacific, Inc. (NASDAQ: JAKK) rose 34.7% to $23.01 in pre-market trading after the company reported ...

Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2022 financial results at approximately 4:00 PM Eastern Time on Thursday, August 11, 2022, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results.

The biotechnology investment fund had the right to terminate the purchase agreement after Athersys laid off three top executives during a restructuring last month.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer, Africa CDC Strikes ...

Athersys, Inc. (Nasdaq: ATHX) today announced that its equity purchase agreement with Aspire Capital Fund LLC (Aspire Capital) has been terminated. The Company continues to evaluate alternative financing options to support continuing operations. After several discussions with Aspire Capital, Athersys received notice on July 6, 2022 of termination of the equity purchase agreement, effective immediately. The equity purchase agreement had been in place since May 12, 2022.

InvestorsObserver issues critical PriceWatch Alerts for COWN, OCFT, FFIE, RMED, and ATHX.

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company ...